NASDAQ$CRBU
Caribou Biosciences Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Caribou Biosciences reported financial results for the first quarter of 2024 and reviewed recent pipeline progress.
Caribou Biosciences reported a net loss of $41.2 million for the first quarter of 2024, with $345.9 million in cash, cash equivalents, and marketable securities as of March 31, 2024. The company is advancing four clinical-stage programs and expects its current cash to fund operations into Q1 2026.
- Advanced CB-010 ANTLER Phase 1 trial for 2L LBCL, with initial dose expansion data to be presented at ASCO 2024.
- Expanded into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024.
- Progressed four clinical-stage programs for hematologic malignancies and autoimmune diseases, anticipating multiple milestones.
- Held $345.9 million in cash, cash equivalents, and marketable securities, expected to fund the current operating plan into Q1 2026.
Headline financials
Revenue & EPS history
Caribou Biosciences · Revenue · Quarterly
$2.43M
Revenue by segment
Caribou Biosciences · $3.76M total across 1 segment · Q2 2023
- Licensing & collaboration$3.76M-10.6%100.0%
Forward guidance
Caribou Biosciences anticipates several milestones across its clinical programs.
Tailwinds
- Presentation of initial dose expansion data for CB-010 in second-line large B cell lymphoma at ASCO 2024.
- Initiation of GALLOP Phase 1 clinical trial for CB-010 in adult patients with lupus nephritis and extrarenal lupus by year-end 2024.
- Presentation of initial dose escalation data from the CaMMouflage Phase 1 clinical trial for CB-011 by year-end 2024.
- Advancement of dose escalation in the AMpLify Phase 1 clinical trial for CB-012 in r/r AML.
- Cash, cash equivalents, and marketable securities are expected to fund the current operating plan into Q1 2026.
Headwinds
- Uncertainties related to the initiation, cost, timing, progress, and results of Caribou’s current and future research and development programs, preclinical studies, and clinical trials
- Risk that initial, preliminary, or interim clinical trial data will not ultimately be predictive of the safety and efficacy of Caribou’s product candidates
- Clinical outcomes may differ as patient enrollment continues and as more patient data becomes available
- Preclinical study results observed will not be borne out in human patients or different conclusions or considerations are reached once additional data have been received and fully evaluated
- Ability to obtain key regulatory input and approvals
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
-0.8%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-5.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+11.1%
Q2 2021
Best reaction
-32.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | +4.1% | -1.5% | |
| Q4 2025 | +6.5% | +15.2% | +13.5% | |
| Q3 2025 | -12.1% | -17.3% | -20.8% | |
| Q1 2025 | +10.5% | +16.7% | +19.4% | |
| Q4 2024 | +0.1% | -8.6% | -22.2% | |
| Q3 2024 | +8.6% | +9.0% | -16.8% | |
| Q2 2024 | -3.1% | -0.8% | -6.4% | |
| Q1 2024 | -8.6% | -7.6% | -45.4% | |
| Q4 2023 | -32.3% | -27.6% | -41.4% | |
| Q3 2023 | -5.0% | -19.3% | +24.7% | |
| Q2 2023 | +5.2% | +5.8% | -12.0% | |
| Q1 2023 | +9.3% | -2.1% | +4.0% | |
| Q4 2022 | -11.8% | -11.4% | -9.9% | |
| Q3 2022 | +3.9% | +15.0% | +2.4% | |
| Q2 2022 | +10.1% | +17.3% | +40.7% | |
| Q1 2022 | -0.5% | +22.4% | +23.7% | |
| Q4 2021 | +2.6% | -5.6% | -16.1% | |
| Q3 2021 | -4.9% | -0.5% | -18.2% | |
| Q2 2021 | +11.1% | +12.3% | -17.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro